tirzepatide surpass-5 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Incidence of mild and severe

Bn cng c th gh cc ca hng m phm ni ting nh Guardian, Watsons, Lixibox hoc cc trung tm thng mi ln nh Emart (chuyn Hn Quc), Aeon (chuyn hng Nht Bn)

Understanding these differences helps determine whether cost savings justify any trade-offs in results or safety

The only FDA-approved semaglutide products are Rybelsus, Ozempic, and Wegovy , manufactured by Novo Nordisk Inc

The good news is that many people report an almost immediate appetite suppression

additional contraceptive methods are advised for 4 weeks after starting treatment and after each dose increase Patients with severe gastrointestinal disease (e.g., gastroparesis) should generally avoid Mounjaro If the patient is on insulin, doses should not be rapidly reduced when starting Mounjaro, as this increases the risk of diabetic ketoacidosis Patients should be counselled to report symptoms suggestive of thyroid C-cell tumours (neck mass, difficulty swallowing, persistent hoarseness) A collaborative approach involving endocrinologists, GPs, and diabetes specialists is often beneficial to ensure comprehensive care and monitoring